Phase 2 is completed (positive results), and they are doing a follow-up trial of this (technically a Phase 1) that is testing whether the immune response can be boosted further. Enrollment for this follow-up trial is complete, and it looks like all follow-up data should be in by the fall of 2018.
News 
Market Data 
Discover 
